Globe Newswire
GENFIT announces satisfactory preliminary results of its OCEANEs’ partial buyback offer
Lille (France), Cambridge (Massachusetts, United States), November 30, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical firm devoted to enhancing the lives of sufferers with metabolic and persistent liver ailments, at present proclaims that: the reverse ebook constructing course of for the partial buyback of GENFIT’s 6,081,081 convertible bonds maturing in October 2022 (“OCEANEs”) achieved passable outcomes and ended on November 27, 2020 (COB) as deliberate; the Bond Buy Agreements from traders having tendered their OCEANEs can be collected as shortly as potential and as soon as the method is accomplished, GENFIT will talk the ultimate outcomes of the partial buyback. ABOUT GENFIT GENFIT is a late-stage biopharmaceutical firm devoted to enhancing the lives of sufferers with cholestatic and metabolic persistent liver ailments. GENFIT is a pioneer within the discipline of nuclear receptor-based drug discovery, with a wealthy historical past and powerful scientific heritage spanning greater than 20 years. GENFIT is at present enrolling in a Part 3 scientific trial evaluating elafibranor in sufferers with major biliary cholangitis (PBC). As a part of GENFIT’s complete strategy to scientific administration of sufferers with liver illness, the Firm can also be creating NIS4™, a brand new, non-invasive blood-based diagnostic expertise which might allow simpler identification of sufferers with at-risk NASH. NIS4™ expertise has been licensed to LabCorp within the U.S. and Canada for the event and commercialization of a blood-based molecular diagnostic check powered by NIS4™ expertise. GENFIT has services in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded firm listed on the Nasdaq International Choose Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com FORWARD LOOKING STATEMENTS This press launch comprises sure forward-looking statements, together with these throughout the which means of the Non-public Securities Litigation Reform Act of 1995, with respect to GENFIT, together with statements concerning our capability to renegotiate the phrases of our OCEANEs and that the ultimate phrases of this proposal can be authorised by the shareholders’ common assembly and common assembly of OCEANEs’ holders. The usage of sure phrases, together with “consider,” “potential,” “count on” and “will” and related expressions, is meant to establish forward-looking statements. Though the Firm believes its expectations are based mostly on the present expectations and cheap assumptions of the Firm’s administration, these forward-looking statements are topic to quite a few identified and unknown dangers and uncertainties, which might trigger precise outcomes to vary materially from these expressed in, or implied or projected by, the forward-looking statements. These dangers and uncertainties embody, amongst different issues, the uncertainties inherent in analysis and improvement, together with associated to security, biomarkers, development of, and outcomes from, its ongoing and deliberate scientific trials, assessment and approvals by regulatory authorities of its drug and diagnostic candidates, alternate price fluctuations and the Firm’s continued capacity to boost capital to fund its improvement, in addition to these dangers and uncertainties mentioned or recognized within the Firm’s public filings with the French Autorité des marchés financiers (“AMF”), together with these listed in Part 4 “Important Dangers and Uncertainties” of the Firm’s 2019 Common Registration Doc filed with the AMF on Could 27, 2020 underneath n° D.20-0503, which is offered on GENFIT’s web site (www.genfit.com) and on the web site of the AMF (www.amf-france.org) and public filings and studies filed with the U.S. Securities and Change Fee (“SEC”), together with the Firm’s 20-F dated Could 27, 2020. As well as, even when the Firm’s outcomes, efficiency, monetary situation and liquidity, and the event of the trade during which it operates are in line with such forward-looking statements, they will not be predictive of outcomes or developments in future intervals. These forward-looking statements converse solely as of the date of publication of this doc. Aside from as required by relevant legislation, the Firm doesn’t undertake any obligation to replace or revise any forward-looking info or statements, whether or not on account of new info, future occasions or in any other case. CONTACT GENFIT | Buyers Naomi EICHENBAUM – Investor Relations | Tel: +1 (617) 714 5252 | traders@genfit.com PRESS RELATIONS | Media Hélène LAVIN – Press relations | Tel: +333 2016 4000 | helene.lavin@genfit.com GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com
Attachment
GENFIT proclaims passable preliminary outcomes of its OCEANEs’ partial buyback supply
Discussion about this post